Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...

2017. Zepbound, an Eli Lilly drug, can now be prescribed to adults with “moderate-to-severe obstructive sleep apnea and obesity” to improve their sleep, a press release from the company said.

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

In a news release published Dec. 20, the FDA stated that Zepbound, a glucagon-like peptide-1 receptor agonist, was cleared to treat moderate-to-severe OSA in patients with obesity. According to ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...